Skip to content
Screener

Theravance Biopharma TBPH Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$26.2MBeat by $7.5M
EPS-$0.08Beat by $0.06
Revenue estimate$18.7M
EPS estimate-$0.14

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$22.0M
EPS estimate$0.24

Financials

Q2 2025

Income statement

See full
Revenue$26.2M+83.7%
Operating income-$2.7M+82.6%
Net income$54.8M+432%
EPS (diluted)$1.08+418%

Balance sheet

See full
Cash & equivalents$281.9M+508%
Total debt$46.5M-0.4%
Total equity$224.8M+16.1%
Total assets$426.0M+17.7%

Cash flow

See full
Operating cash flow$208.1M+4,813%
Free cash flow$59.6M+1,440%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$533.51M+30.3%
Enterprise value$298.04M-27.3%
P/E40.9×—
P/S6.9×+0.3×

Profitability

See full
Operating margin-48.2%-10.7pp
Net margin16.9%+9.3pp
FCF margin146.3%+134pp

Returns & leverage

See full
Return on equity6.2%+3.5pp
Debt / equity0.2×0.0×
Current ratio6.7×+1.5×

Segments

By segment

See full
Single Reportable$26.2M+83.7%

By product

See full
Collaborative Arrangement Revenue$18.7M+31.1%

FAQ

When did Theravance Biopharma report Q2 2025 earnings?
Theravance Biopharma (TBPH) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Theravance Biopharma's Q2 2025 revenue and EPS?
Theravance Biopharma reported revenue of $26.2M and eps of $-0.08 for Q2 2025.
Did Theravance Biopharma beat estimates in Q2 2025?
Revenue beat the consensus estimate of $18.7M by $7.5M. EPS beat the consensus estimate of $-0.14 by $0.06.
How did Theravance Biopharma's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 83.7% from $14.3M a year earlier and eps grew 38.5% from $-0.13.
Where can I find Theravance Biopharma's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-076837) and the 10-Q periodic report (0001558370-25-011408) directly on SEC EDGAR. The filing index links above go to sec.gov.